RNXT
RenovoRx Inc

3,287
Mkt Cap
$36.65M
Volume
276,541.00
52W High
$1.45
52W Low
$0.7006
PE Ratio
-2.81
RNXT Fundamentals
Price
$1.00
Prev Close
$1.01
Open
$1.03
50D MA
$0.9512
Beta
0.98
Avg. Volume
170,505.05
EPS (Annual)
-$0.3958
P/B
4.54
Rev/Employee
$4,300.00
$21.85
Loading...
Loading...
News
all
press releases
CytomX Therapeutics (CTMX) Reports Q4 Loss, Misses Revenue Estimates
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -175.00% and -90.98%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6d ago
News Placeholder
More News
News Placeholder
Oculis Holding AG (OCS) Reports Q4 Loss, Tops Revenue Estimates
Oculis Holding AG (OCS) delivered earnings and revenue surprises of -17.70% and +83.68%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·19d ago
News Placeholder
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors $668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors PR Newswire VANCOUVER, BC, Jan. 30, 2026 Issued on behalf of...
PR Newswire·2mo ago
News Placeholder
RenovoRx, Inc. (RNXT) Reports Q3 Loss, Lags Revenue Estimates
RenovoRx (RNXT) delivered earnings and revenue surprises of 0.00% and -35.12%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation PR Newswire VANCOUVER, BC, Oct. 17, 2025...
PR Newswire·5mo ago
News Placeholder
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwrights 27th Annual Global Investment Conference in New York City, September 8-10, 2025
RenovoRx, Inc. (RenovoRx or the Company) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a patented, FDA-cleared...
Business Wire·7mo ago
News Placeholder
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Tops Revenue Estimates
RenovoRx (RNXT) delivered earnings and revenue surprises of 0.00% and +22.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7mo ago
News Placeholder
RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates
Zacks·10mo ago
<
...
1
>

Latest RNXT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.